{"id":487027,"date":"2026-05-16T02:27:10","date_gmt":"2026-05-16T02:27:10","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/487027\/"},"modified":"2026-05-16T02:27:10","modified_gmt":"2026-05-16T02:27:10","slug":"clinical-trial-assessing-mscs-in-mild-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/487027\/","title":{"rendered":"Clinical Trial Assessing MSCs in Mild Alzheimer’s Disease"},"content":{"rendered":"

Original story from the University of Miami Miller School of Medicine (FL, USA).<\/a><\/p>\n

A new clinical trial is evaluating whether a single mesenchymal stem cell infusion can stabilize cognitive decline in patients with mild cognitive impairment or early Alzheimer\u2019s disease.<\/strong><\/p>\n

A new investigator-initiated clinical trial at the University of Miami Miller School of Medicine is exploring whether a single infusion of mesenchymal stem cells can stabilize cognitive decline in patients with mild cognitive impairment or early\u00a0Alzheimer\u2019s disease.<\/p>\n

The trial, led by\u00a0Barry Baumel,\u00a0an associate professor of\u00a0neurology\u00a0and director of\u00a0memory disorders clinical trials at the University of Miami Miller School of Medicine, builds on both emerging standard-of-care therapies and earlier stem cell research in which Baumel participated, including a published phase I clinical trial investigating Lomecel\u2011B, a mesenchymal stem cell\u2013based therapy.<\/p>\n

\u201cWhat I want to see, in this group that\u2019s being treated to slow their disease, is if we can stabilize so it stops getting worse,\u201d Baumel said.<\/p>\n

The current study targets patients already receiving anti-amyloid monoclonal antibody therapies (Leqembi\u00a0or\u00a0Kisunla) that are widely used in early Alzheimer\u2019s disease. These drugs remove amyloid plaque and slow disease progression but do not halt or reverse it.<\/p>\n

\u201cWe have data that shows us how people do on these drugs,\u201d Baumel said. \u201cIt\u2019s like a ski slope. Over time, the slope changes. It\u2019s still a ski slope, but it\u2019s not as steep a ski slope, if you take the medications. You end up going down the hill slower.\u201d<\/p>\n

The trial adds a one-time intravenous infusion of human mesenchymal stem cells (hMSCs) to see if they can further improve outcomes. Participants will be monitored longitudinally following the stem cell infusion, with outcomes focused on whether cognitive decline stabilizes or improves.<\/p>\n

The study intentionally delays the stem cell treatment until patients have already been on monoclonal antibody therapy for six months, minimizing confounding safety signals from overlapping treatments.<\/p>\n

Who qualifies for the Alzheimer\u2019s clinical trial?<\/p>\n

The trial focuses on individuals in the early stages of Alzheimer\u2019s disease.<\/p>\n

Eligible participants must:<\/p>\n